LenioBio ads

Attending Discovery on Target in Boston? Meet LenioBio at Booth #309 to discuss your hardest protein target. Request a meeting with our team.

Every week troubleshooting expression is a week behind. ALiCE® runs in 48 hours. Data comes back while decisions are still cheap.

Membrane protein won’t express? Cells have limits. ALiCE doesn’t. ALiCE expresses full-length membrane proteins in their native membrane environment - properly folded and displayed.

Membrane proteins are vital for how cells communicate, regulate signals, and respond to their environment. But, they are also among the most challenging targets in drug discovery. 🔹 Central to cell signaling, regulation, and disease pathways 🔹 Often fail to express in full length or correct conformation in cell-based systems 🔹 Misfolding and missing PTMs limit progress in structural and therapeutic research That’s where ALiCE® changes the game. ✅ A eukaryotic cell-free protein expression platform for rapid, high-yield production ✅ Generates functional, full-length membrane proteins with native PTMs ✅ Suitable for complex targets like RTKs and GPCRs ✅ Delivers properly folded, soluble proteins ready for downstream assays Using ALiCE®, the University of Leeds team successfully expressed full-length, functional FGFR3-TACC3, an oncogenic receptor tyrosine kinase previously deemed too complex for cell-based systems. 📖 Learn how this breakthrough is helping researchers unlock novel cancer targets: 👉 https://cstu.io/47d248 #MembraneProteins #ProteinExpression #RTK #GPCR #StructuralBiology #DrugDiscovery #CellFree #ALiCE #LenioBio #DrugTarget #SolubleProteins #FunctionalExpression #CancerResearch #ComplexTargets #DiseasePathways #ProteinFolding Mark F. Remberto Martis Jim Nowak Lisa Held Maja Lieven (née Rennig), PhD Christiaan van den Berg

🤝 mAIbe and LenioBio are launching an impactful new collaboration that unites AI-driven antibody design with ultrafast cell-free protein expression. By integrating our complementary technologies, we aim to significantly accelerate the design–build–test cycle for next-generation monoclonal antibodies. This partnership enables rapid functional testing of AI-generated candidates and the generation of high-quality experimental data to iteratively improve discovery models. Together, we are working to set a new standard for speed and efficiency in therapeutic antibody innovation. 📢 Read more: https://cstu.io/754eb7 #AI #Antibodies #Biotechnology #CellFree #Innovation #Partnership #DrugDiscovery #LabInTheLoop #DeNovoProteins Andre Goerke Remberto Martis Thomas Palm Jonathan Fauerbach (PhD, MBA) Hugh Watson Mark F. Jim Nowak Lisa Held Maja Lieven (née Rennig), PhD Christiaan van den Berg

Accelerate your Antibody Discovery 10X with ALiCE® HTPE - the first eukaryotic cell-free platform designed to slash timelines, costs, and labor in your current workflow.